Daurismo for Newly Diagnosed AML

News
Article

Daurismo Product Image

Daurismo (glasdegib, Pfizer)

Indications: Newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years old or older and have comorbidities that preclude use of intensive induction chemotherapy

Dosage: 100 mg orally, once daily.

Contraindications: None

Click here for more prescribing information

Recent Videos
Related Content
FDA Updates Veozah Label With Boxed Warning for Rare But Serious Liver Injury

FDA Updates Veozah Label With Boxed Warning for Rare But Serious Liver Injury

Lauren Biscaldi, MS, Managing Editor
December 18th 2024
Article

The patient’s symptoms gradually resolved after discontinuing fezolinetant therapy.

Over the Counter podcast

Episode 8: Stay in Sync with Innovations in Medication Decision Support

Drug Topics staff
August 6th 2020
Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

FDA Roundup: ATX101 Gains Breakthrough Therapy Designation, Stelara Biosimilar Approval

FDA Roundup: ATX101 Gains Breakthrough Therapy Designation, Stelara Biosimilar Approval

Killian Meara
December 6th 2024
Article

Catch up on important FDA news from the week of December 2.

FDA Approves Acoramidis for ATTR-CM

FDA Approves Acoramidis for ATTR-CM

Lauren Biscaldi, MS, Managing Editor
November 25th 2024
Article

This approval marks the availability of the first near-complete stabilizer of transthyretin.

FDA Accepts BLA Resubmission for Epidermolysis Bullosa Gene Therapy

FDA Accepts BLA Resubmission for Epidermolysis Bullosa Gene Therapy

Killian Meara
November 12th 2024
Article

The agency assigned prademagene zamikeracel a PDUFA target action date of April 29, 2025.

FDA Roundup: Rosacea Treatment, Proposal to Remove Oral Phenylephrine from OTC Products

FDA Roundup: Rosacea Treatment, Proposal to Remove Oral Phenylephrine from OTC Products

Killian Meara
November 8th 2024
Article

Check out these important FDA updates from the week of November 4.

© 2024 MJH Life Sciences

All rights reserved.